Wogonin affects proliferation and the energy metabolism of SGC‑7901 and A549 cells

Wang,Shu‑Jing; Zhao,Jian‑Kai; Ren,Shuang; Sun,Wei‑Wei; Zhang,Wen‑Jun; Zhang,Jia‑Ning

doi:10.3892/etm.2018.7023

Wogonin affects proliferation and the energy metabolism of SGC‑7901 and A549 cells

Authors:
- Shu‑Jing Wang
- Jian‑Kai Zhao
- Shuang Ren
- Wei‑Wei Sun
- Wen‑Jun Zhang
- Jia‑Ning Zhang
View Affiliations

Affiliations: College of Pharmacy, Harbin University of Commerce, Harbin, Heilongjiang 150076, P.R. China
Published online on: November 28, 2018 https://doi.org/10.3892/etm.2018.7023
Pages: 911-918

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Many studies have focused on the identification of therapeutic targets for the treatment of certain types of cancer. Wogonin is a natural flavonoid compound that exhibits a potent anti‑cancer effect. The underlying mechanism of wogonin may therefore reveal an effective way to identify novel therapeutic targets. In the current study, growth curves and MTT assays were performed to determine the effects of wogonin in human gastric cancer cells (SGC‑7901) and human lung adenocarcinoma cells (A549), respectively. Changes in morphology were observed using hematoxylin and eosin (H&E) staining. The activities of key enzymes in the glycolysis and tricarboxylic acid cycle were measured using spectrophotometry. Western blot analysis was performed to determine the expression levels of hypoxia inducible factor‑1α (HIF‑1α) and monocarboxylate transporter‑4 (MCT‑4). Wogonin inhibited cell proliferation in a time‑ and dose‑dependent manner in SGC‑7901 and A549 cells. H&E staining suggested that wogonin induced cell morphology changes. In SGC‑7901 cells, lactate dehydrogenase (LDH) and succinate dehydrogenase (SDH) activities and adenosine triphosphate (ATP) generation were decreased significantly by wogonin treatment compared with the untreated control. In A549 cells, wogonin significantly reduced LDH activity, but exhibited no significant effects on kinase activities or ATP generation. Furthermore, wogonin significantly decreased HIF‑1α and MCT‑4 protein expression in SGC‑7901 cells, but not in A549 cells. The results demonstrated that wogonin inhibited the energy metabolism, cell proliferation and angiogenesis in SGC‑7901 and A549 cells by negatively regulating HIF‑1α and MCT‑4 expression. The differential regulatory roles of wogonin in metabolism‑associated enzymes in human gastric cancer and lung adenocarcinoma cells indicated its various antitumor mechanisms. The different metabolic regulatory mechanisms exhibited by wogonin in different tumor tissues should therefore be considered for antitumor therapy.

View Figures

View References

1	Tai MC, Shui YT, Chang LY and Xue H: Therapeutic potential of wogonin: A naturally occurring flavonoid. CNS Drug Rev. 11:141–150. 2005. View Article : Google Scholar : PubMed/NCBI
2	Huang KF, Zhuang Y, Huang YQ and Diao Y: Experimental study on inhibitory effect of wogonin on proliferation and invasion of breast cancer cells. Zhongguo Zhong Yao Za Zhi. 39:1485–1489. 2014.(In Chinese). PubMed/NCBI
3	Li XD: Inhibitory effects of wogonin on lung cancer A549 cell line in vitro. J Chongqing Med Univ. 7:790–793. 2011.(In Chinese).
4	Ding J, Polier G, Köhler R, Giaisi M, Krammer PH and Li-Weber M: Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression. J Biol Chem. 287:641–649. 2012. View Article : Google Scholar : PubMed/NCBI
5	Hong ZP, Wang LG, Wang HJ, Ye WF and Wang XZ: Wogonin exacerbates the cytotoxic effect of oxaliplatin by inducing nitrosative stress and autophagy in human gastric cancer cells. Phytomedicine. 39:168–175. 2018. View Article : Google Scholar : PubMed/NCBI
6	Lu X, Wu XL, Li Y, Peng Y and Chen PF: Inhibitory effect of wogonin on gastric cancer SGC 7901 cell line in vitro. J Chin Pharm Sci. 46:512–517. 2011.
7	Bauman S, Fas SC, Giaisi M, Müller WW, Merling A, Gülow K, Edler L, Krammer PH and Li-Weber M: Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCC1 and Ca²⁺ dependent apoptosis. Blood. 11:2354–2363. 2008. View Article : Google Scholar
8	Lin CM, Chang H, Chen YH, Wu IH and Chiu JH: Wogonin inhibits IL6 induced angiogenesis via downregulation of VEGF and VEGFR-1, not VEGFR-2. Planta Med. 72:1305–1312. 2006. View Article : Google Scholar : PubMed/NCBI
9	Lu N, Gao Y, Ling Y, Chen Y, Yang Y, Gu HY, Qi Q, Liu W, Wang XT, You QD and Guo QL: Wogonin suppresses tumor growth in vivo and VEGF induced angiogenesis through inhibiting tyrosine phosphorylation of VEGFR-2. Life Sci. 82:956–963. 2008. View Article : Google Scholar : PubMed/NCBI
10	Wang HW, Lin CP, Chiu JH, Chow KC, Kuo KT, Lin CS and Wang LS: Reversal of inflammation as sociated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin. Int J Cancer. 120:2019–2027. 2007. View Article : Google Scholar : PubMed/NCBI
11	Chow KC, Lu MP and Wu MT: Expression of dihydrodiol dehydrogenase plays important roles in apoptosis and drug resistance of A431 squamous cell carcinoma. J Dermatol Sci. 41:205–212. 2006. View Article : Google Scholar : PubMed/NCBI
12	Penning TM, Jin Y, Steckelbroeck S, Lanisnik Rizner T and Lewis M: Structure function of human 3 alpha-hydroxysteroid dehydrogenases: Genes and proteins. Mol Cell Endocrinol. 215:63–72. 2004. View Article : Google Scholar : PubMed/NCBI
13	Zhang HW, Yang Y, Zhang K, Qiang L, Yang L, Yang L, Hu Y, Wang XT, You QD and Guo QL: Wogonin induced differentiation and G1 phase arrest of human U-937 leukemia cells via PKC delta phosphorylation. Eur J Pharmacol. 591:7–12. 2008. View Article : Google Scholar : PubMed/NCBI
14	Cho J and Lee HK: Wogonin inhibits excitotoxic and oxidative neuronal damage in primary cultured rat cortical cells. Eur J Pharmacol. 485:105–110. 2004. View Article : Google Scholar : PubMed/NCBI
15	Ma SC, Du J, But PP, Deng XL, Zhang YW, Ooi VE, Xu HX, Lee SH and Lee SF: Antiviral Chinese medicinal herbs against respiratory syncytial virus. J Ethnopharmacol. 79:205–211. 2002. View Article : Google Scholar : PubMed/NCBI
16	Xiao WM, Bu P and Gong WJ: Advance in studies on antitumor and immunomodulatory effects of wogonin. Zhongguo Zhong Yao Za Zhi. 39:3004–3009. 2014.(In Chinese). PubMed/NCBI
17	Cantor JR and Sabatini DM: Cancer cell metabolism: One hallmark, many faces. Cancer Discov. 2:881–898. 2012. View Article : Google Scholar : PubMed/NCBI
18	Warburg O, Wind F and Negelein E: The metabolism of tumors in the body. J Gen Physiol. 8:519–530. 1927. View Article : Google Scholar : PubMed/NCBI
19	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
20	Dong B and Zhu YM: Molecular-tareted therapy for cancer. Chin J Cancer. 29:340–345. 2010. View Article : Google Scholar : PubMed/NCBI
21	Koppenol WH, Bounds PL and Dang CV: Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 11:325–337. 2011. View Article : Google Scholar : PubMed/NCBI
22	Batool S, Joseph TP, Hussain M, Vuai MS, Khinsar KH, Din SRU, Padhiar AA, Zhong M, Ning A, Zhang W, et al: LP1 from Lentinula edodes C91-3 induces autophagy, apoptosis and reduces metastasis in human gastric cancer cell line SGC-7901. Int J Mol Sci. 19(pii): E29862018. View Article : Google Scholar : PubMed/NCBI
23	Park YJ, Lee SR, Kim DM, Yu JS, Beemelmanns C, Chung KH and Kim KH: The inhibitory effects of cyclodepsipeptides from the entomopathogenic fungus beauveria bassiana on myofibroblast differentiation in A549 alveolar epithelial cells. Molecules. 23(pii): E25682018. View Article : Google Scholar : PubMed/NCBI
24	Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
25	Kim EH, Shim B, Kang S, Jeong G, Lee JS, Yu YB and Chun M: Anti-inflammatory effects of Scutellaria baicalensis extract via suppression of immune modulators and MAP kinase signaling molecules. J Ethnopharmacol. 126:320–331. 2009. View Article : Google Scholar : PubMed/NCBI
26	Wang M, Zhao X, Zhu D, Liu T, Liang X, Liu F, Zhang Y, Dong X and Sun B: HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment. J Exp Clin Cancer Res. 36:602017. View Article : Google Scholar : PubMed/NCBI
27	Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV and Lenz HJ: ERCC1 and thymidy-late synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 19:4298–4304. 2001. View Article : Google Scholar : PubMed/NCBI
28	de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced col-orectal cancer. J Clin Oncol. 18:2938–2947. 2000. View Article : Google Scholar : PubMed/NCBI
29	Hsu PP and Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell. 134:703–707. 2008. View Article : Google Scholar : PubMed/NCBI
30	Bartrons R and Caro J: Hypoxia, glucose metabolism and the Warburg's effect. J Bioenerg Biomembr. 39:223–229. 2007. View Article : Google Scholar : PubMed/NCBI
31	Zhang BY, Qu QX and Gu AK: Expression and clinical significance of CD147, MCT4 in cervical lesions. J Int Obstet Gynecol. 42:194–196. 2015.
32	Pietras A, Johnsson AS and Påhlman S: The HIF-2α-driven pseudo-hypoxic phenotype in tumor aggressiveness, differentiation, and vascularization. Curr Top Microbiol Immunol. 345:1–20. 2010.PubMed/NCBI
33	Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, Hawkins C and Guha A: Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. Cell. 208:313–326. 2011.
34	Chen J, Xie J, Jiang Z, Wang B, Wang Y and Hu X: Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene. 30:4297–4306. 2011. View Article : Google Scholar : PubMed/NCBI
35	Trufelli DC, Moraes TV, Lima AA and Giglio AD: Epidemiological profile and prognostic factors in patients with lung cancer. Rev Assoc Med Bras (1992). 62:428–433. 2016. View Article : Google Scholar : PubMed/NCBI
36	Kroemer G and Pouyssegur J: Tumor cell metabolism: Cancers Achilles heel. Cancer Cell. 13:472–482. 2008. View Article : Google Scholar : PubMed/NCBI
37	Fukumura D, Xu L, Chen Y, Gohongi T, Seed B and Jain RK: Hypoxia and acidosis independently upregulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 61:6020–6024. 2001.PubMed/NCBI
38	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
39	Chan AK, Bruce JI and Siriwardena AK: Glucose metabolic phenotype of pancreatic cancer. World J Gastroenterol. 22:3471–3485. 2016. View Article : Google Scholar : PubMed/NCBI
40	Mansouri S, Shahriari A, Kalantar H, Moini Zanjani T and Haghi Karamallah M: Role of malate dehydrogenase in facilitating lactate dehydrogenase to support the glycolysis pathway in tumors. Biomed Rep. 6:463–467. 2017. View Article : Google Scholar : PubMed/NCBI
41	Ghezzi D, Goffrini P, Uziel G, Horvath R, Klopstock T, Lochmüller H, D'Adamo P, Gasparini P, Strom TM, Prokisch H, et al: SDHAF1, encoding a LYR complex-II specific assembly factor, is mutated in SDH-defective infantile leukoencephalopathy. Nat Genet. 41:654–656. 2009. View Article : Google Scholar : PubMed/NCBI
42	Pecsi I, Hards K, Ekanayaka N, Berney M, Hartman T, Jacobs WR Jr and Cook GM: Essentiality of succinate dehydrogenase in Mycobacterium smegmatis and its role in the generation of the membrane potential under hypoxia. MBio. 5(pii): e01093–14. 2014.PubMed/NCBI
43	Pucino V, Cucchi D and Mauro C: Lactate transporters as therapeutic targets in cancer and inflammatory diseases. Expert Opin Ther Targets. 22:735–743. 2018. View Article : Google Scholar : PubMed/NCBI
44	Han K, Xu X, Chen G, Zeng Y, Zhu J, Du X, Zhang Z, Cao B, Liu Z and Mao X: Identification of apromising PI3K inhibitor for the treatment of multiple myeloma throughthe structural optimization. J Hematol Oncol. 7:92014. View Article : Google Scholar : PubMed/NCBI
45	Wallace DC: Mitochondria and cancer: Warburg addressed. Cold Spring Harb Symp Quant Biol. 70:363–374. 2005. View Article : Google Scholar : PubMed/NCBI
46	Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ and Abraham RT: Regulation of hypoxiainducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 22:7004–7014. 2002. View Article : Google Scholar : PubMed/NCBI
47	Semenza GL: HIF-1: Upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 20:51–56. 2010. View Article : Google Scholar : PubMed/NCBI